Congenital Long QT Syndrome: A Focus on Risk Stratification and Management
Congenital long QT syndrome (LQTs) is an inherited cardiac condition resulting from cardiac repolarization abnormalities. Since the initial description of congenital LQTs by Jervell and Lange-Nielsen in 1957, our understanding of this condition has increased dramatically. A diagnosis of congenital L...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-06-01
|
| Series: | Reviews in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/RCM/26/6/10.31083/RCM36779 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849427585261371392 |
|---|---|
| author | Deepti Ranganathan Steffany Grondin Raouane Hadjeres Jacqueline Joza |
| author_facet | Deepti Ranganathan Steffany Grondin Raouane Hadjeres Jacqueline Joza |
| author_sort | Deepti Ranganathan |
| collection | DOAJ |
| description | Congenital long QT syndrome (LQTs) is an inherited cardiac condition resulting from cardiac repolarization abnormalities. Since the initial description of congenital LQTs by Jervell and Lange-Nielsen in 1957, our understanding of this condition has increased dramatically. A diagnosis of congenital LQTs is based on the medical history of the patient, alongside electrogram features, and a genetic variant that is identified in approximately 75% of cases. The appropriate risk stratification involves a multitude of factors, with β-blockers being the cornerstone of therapy. Recent developments, such as the incorporation of artificial intelligence (AI) for electrocardiogram (ECG) interpretation, genotype–phenotype-specific therapies, and emerging gene therapies, may potentially make personalized medicine in LQTs a reality in the near future. This review summarizes our current understanding of congenital LQTs, with a focus on risk stratification, current therapeutic interventions, and emerging developments in the management of congenital LQTs. |
| format | Article |
| id | doaj-art-01f8629f13aa4bd89bad26819e0f960c |
| institution | Kabale University |
| issn | 1530-6550 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Reviews in Cardiovascular Medicine |
| spelling | doaj-art-01f8629f13aa4bd89bad26819e0f960c2025-08-20T03:28:59ZengIMR PressReviews in Cardiovascular Medicine1530-65502025-06-012663677910.31083/RCM36779S1530-6550(25)01871-XCongenital Long QT Syndrome: A Focus on Risk Stratification and ManagementDeepti Ranganathan0Steffany Grondin1Raouane Hadjeres2Jacqueline Joza3Department of Cardiology, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaDepartment of Cardiology, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaDepartment of Cardiology, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaDepartment of Cardiology, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaCongenital long QT syndrome (LQTs) is an inherited cardiac condition resulting from cardiac repolarization abnormalities. Since the initial description of congenital LQTs by Jervell and Lange-Nielsen in 1957, our understanding of this condition has increased dramatically. A diagnosis of congenital LQTs is based on the medical history of the patient, alongside electrogram features, and a genetic variant that is identified in approximately 75% of cases. The appropriate risk stratification involves a multitude of factors, with β-blockers being the cornerstone of therapy. Recent developments, such as the incorporation of artificial intelligence (AI) for electrocardiogram (ECG) interpretation, genotype–phenotype-specific therapies, and emerging gene therapies, may potentially make personalized medicine in LQTs a reality in the near future. This review summarizes our current understanding of congenital LQTs, with a focus on risk stratification, current therapeutic interventions, and emerging developments in the management of congenital LQTs.https://www.imrpress.com/journal/RCM/26/6/10.31083/RCM36779long qt syndromeqt prolongationrisk stratification |
| spellingShingle | Deepti Ranganathan Steffany Grondin Raouane Hadjeres Jacqueline Joza Congenital Long QT Syndrome: A Focus on Risk Stratification and Management Reviews in Cardiovascular Medicine long qt syndrome qt prolongation risk stratification |
| title | Congenital Long QT Syndrome: A Focus on Risk Stratification and Management |
| title_full | Congenital Long QT Syndrome: A Focus on Risk Stratification and Management |
| title_fullStr | Congenital Long QT Syndrome: A Focus on Risk Stratification and Management |
| title_full_unstemmed | Congenital Long QT Syndrome: A Focus on Risk Stratification and Management |
| title_short | Congenital Long QT Syndrome: A Focus on Risk Stratification and Management |
| title_sort | congenital long qt syndrome a focus on risk stratification and management |
| topic | long qt syndrome qt prolongation risk stratification |
| url | https://www.imrpress.com/journal/RCM/26/6/10.31083/RCM36779 |
| work_keys_str_mv | AT deeptiranganathan congenitallongqtsyndromeafocusonriskstratificationandmanagement AT steffanygrondin congenitallongqtsyndromeafocusonriskstratificationandmanagement AT raouanehadjeres congenitallongqtsyndromeafocusonriskstratificationandmanagement AT jacquelinejoza congenitallongqtsyndromeafocusonriskstratificationandmanagement |